Olcegepant

SKU: orb1309304

Description

Olcegepant (BIBN-4096) is a potent and highly selective small-molecule antagonist of the human CGRP1 receptor, exhibiting sub-nanomolar affinity (Ki = 14.4 pM). It is widely used in migraine research to investigate CGRP receptor function in both in vitro binding assays and in vivo animal models of neurogenic inflammation and vasodilation.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 204697-65-4
• MW: 869.65
• Purity: 98.16% (May vary between batches)
• Formula: C₃₈H₄₇Br₂N₉O₅
• SMILES: O=C1N(CC=2C(N1)=CC=CC2)C3CCN(C(N[C@H](CC4=CC(Br)=C(O)C(Br)=C4)C(N[C@H](C(=O)N5CCN(CC5)C=6C=CN=CC6)CCCCN)=O)=O)CC3
• Target: CGRP Receptor
• Solubility: DMSO:23.81 mg/mL (27.38 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (2.3 mM)

Bioactivity

• Target IC50:
  CGRP (human):14.4 pM (ki)|CGRP1:0.03 nM
• In Vivo:
  Pre-treatment with Olcegepant (900 μg/kg) inhibits capsaicin-induced Fos expression in the spinal trigeminal nucleus by 57%, without altering phosphorylated extracellular signal-regulated kinase expression in the trigeminal ganglion. Olcegepant (1-30 μg/kg, i.v.) suppresses CGRP effects on facial blood flow in marmosets and significantly reduces mechanical allodynia in CCI-ION rats (0.3-0.9 mg/kg, i.v.). Additionally, Olcegepant (0.6 mg/kg, i.v.) decreases c-Fos immunolabeled cells and ATF3 transcript upregulation, but not interleukin-6, in the trigeminal ganglion of CCI-ION rats .
  Read more...
• In Vitro:
  Olcegepant exhibits exceptional efficacy at primate CGRP receptors, demonstrating a high affinity (Ki) of 14.4±6.3 (n=4) pM for human CGRP receptors, surpassing that of the endogenous ligand CGRP and demonstrating a 150-fold greater affinity than the peptidic antagonist CGRP8-37. It competitively antagonizes CGRP-induced concentration-dependent relaxation, effectively reversing CGRP-mediated vasodilation in human cerebral vessels and inhibiting neurogenic vasodilation in a surrogate animal model for migraine pathophysiology. This suggests that Olcegepant, acting as a CGRP receptor antagonist, may be a potential novel abortive treatment for migraines. Its competitive antagonism has also been confirmed in SK-N-MC cells, with its effects observed in isolated human cerebral, coronary, and omental arteries using sensitive myograph techniques.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BIBN 4096, BIBN 4096BS, BIBN4096, BIBN-4096, Calcitonin gene-related peptide receptor, CGRP1, CGRPReceptor, CGRP Receptor, Olcegepant, inhibit, Inhibitor, hCGRP

Compound Identifiers

PubChem CID

6918509